Cellero Leadership Team

Innovation is in our blood. Cellero is led by a unique combination of Ph.D. research scientists, board-certified physicians, and innovative biotech entrepreneurs. Get to know our team.

Jeff Allen

Jeffrey D. Allen

General Manager

Jeff joined the company as President and CEO in January 2019 to integrate and lead the Key Biologics and Astarte Biologics organizations, which had been acquired by Ampersand Capital in 2018. Jeff was the driving force behind the formation of the Cellero brand, which represents the combined capabilities of both companies to provide the most comprehensive service offering in the field. He is uniquely suited for leading the company with his extensive background in healthcare and life sciences, and his strengths in strategy and business development. Jeff is now General Manager of HemaCare, a Charles River Company.

Jeff is an engaging leader who is very committed to creating strong, dynamic teams, and delivering the very best in service and quality products to meet the needs of customers and other key stakeholders.

Jeff’s background includes over 15 years with Baxter Healthcare in a wide range of finance and business development leadership roles in the fields of cardiovascular, renal, and xenotransplantation. He spent another 15 years leading strategy, finance, and operations for several transfusion medicine organizations across the U.S.

Jeff holds an MBA in international business from the University of California-Irvine and a BS in finance from Northern Illinois University.

Scott Carter

A. Scott Carter

Executive Director Operations

Scott Carter has spent two decades in the medical field in various leadership roles in immunohematology, compliance and quality assurance, community relations, business development and sales, and overall operations management, including 14 years dedicated to cell therapy progress as Director of Operations for Key Biologics and its predecessor organization, Lifeblood Biological Services.

Scott utilizes his apheresis and blood center operational experience to work with medical and academic researchers across the U.S. and around the world to help accelerate research and development efforts in the cell and gene therapy field. He has worked with the developers of the first FDA-approved immune cell therapy and their patients in treatment and ongoing national clinical trials, helped medical device companies in the cell therapy field to reach regulatory approval in the U.S. for new devices, and collaborated with new cell therapy companies to educate them on leukapheresis product collection, procurement, and logistics best practices.

Scott is a licensed Medical Technologist and started his career at St. Jude Children’s Research Hospital in Memphis after graduating from the University of Tennessee in 1999.

Sandra Dorothy

Sandra Dorothy, MT(ASCP)SBB, CQA(ASQ)CQM/OE

Associate Director QA & RA

Sandra Dorothy has more than 20 years’ experience in medical laboratory science and blood product manufacturing, and has served in leadership roles in quality management, regulatory affairs, project management, and validation.

Sandra is an ASCP certified Medical Technologist and Specialist in Blood Banking, an ASQ Certified Quality Auditor and Certified Manager of Quality/Organizational Excellence. Sandra has a Bachelor of Science from Rhode Island College.